{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:53:54Z","timestamp":1781859234528,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007816","name":"Alcon Laboratories Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajo.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:11:39Z","timestamp":1768691499000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1\/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-1506","authenticated-orcid":false,"given":"TOMOYUKI","family":"WADA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAZUNORI","family":"OMATSU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEPHEN C.","family":"PFLUGFELDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2026.01.009_bib0001","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.009_bib0002","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtos.2016.09.003","article-title":"New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society","volume":"15","author":"Tsubota","year":"2017","journal-title":"Ocul Surf"},{"issue":"8","key":"10.1016\/j.ajo.2026.01.009_bib0004","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/jcm8081120","article-title":"Treatment trends in dry eye disease and factors associated with ophthalmic follow-up discontinuation in Japan","volume":"8","author":"Uchino","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000360","article-title":"Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries","volume":"4","author":"Messmer","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.ajo.2026.01.009_bib0006","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2026.01.009_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/OPTH.S233194","article-title":"Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease","volume":"14","author":"White","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/neu.20079","article-title":"Thermosensation and pain","volume":"61","author":"Tominaga","year":"2004","journal-title":"J Neurobiol"},{"issue":"6653","key":"10.1016\/j.ajo.2026.01.009_bib0009","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1167\/iovs.10-5801","article-title":"TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells","volume":"52","author":"Pan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.009_bib0011","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","article-title":"Neuropathic pain and dry eye","volume":"16","author":"Galor","year":"2018","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ajo.2026.01.009_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.598678","article-title":"Chronic tear deficiency sensitizes transient receptor potential vanilloid 1-mediated responses in corneal sensory nerves","volume":"14","author":"Masuoka","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"10","key":"10.1016\/j.ajo.2026.01.009_bib0014","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1167\/iovs.11-7266","article-title":"Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays","volume":"52","author":"Boehm","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2026.01.009_bib0015","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ophtha.2012.05.038","article-title":"Change in prostaglandin expression levels and synthesizing activities in dry eye disease","volume":"119","author":"Shim","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2026.01.009_bib0016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archophthalmol.2011.200","article-title":"Alterations of tear neuromediators in dry eye disease","volume":"129","author":"Lambiase","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.01.009_bib0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1113\/expphysiol.2006.035642","article-title":"Role of TRPV ion channels in sensory transduction of osmotic stimuli in mammals","volume":"92","author":"Liedtke","year":"2007","journal-title":"Exp Physiol"},{"issue":"6","key":"10.1016\/j.ajo.2026.01.009_bib0018","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/j.pain.0000000000000527","article-title":"Targeted overexpression of tumor necrosis factor-\u03b1 increases cyclin-dependent kinase 5 activity and TRPV1-dependent Ca2+ influx in trigeminal neurons","volume":"157","author":"Rozas","year":"2016","journal-title":"Pain"},{"issue":"19","key":"10.1016\/j.ajo.2026.01.009_bib0019","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1523\/JNEUROSCI.0233-08.2008","article-title":"Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons","volume":"28","author":"Schnizler","year":"2008","journal-title":"J Neurosci"},{"issue":"22","key":"10.1016\/j.ajo.2026.01.009_bib0020","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1523\/JNEUROSCI.3993-14.2015","article-title":"Persistent nociception triggered by nerve growth factor (NGF) is mediated by TRPV1 and oxidative mechanisms","volume":"35","author":"Eskander","year":"2015","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2026.01.009_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2016.10.003","article-title":"The intriguing role of neuropeptides at the ocular surface","volume":"15","author":"Sabatino","year":"2017","journal-title":"Ocul Surf"},{"issue":"1\u20132","key":"10.1016\/j.ajo.2026.01.009_bib0022","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2008.01.024","article-title":"Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans","volume":"136","author":"Gavva","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.ajo.2026.01.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107474","article-title":"Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis","volume":"208","author":"Garami","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ajo.2026.01.009_bib27","unstructured":"Tarui T, Kobayashi S. Pharmaceutical drug containing heterocyclidene acetamide derivative. World Intellectual Property Organization Patent. WO2021\/066144:2021. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2021066144&_cid=P10-MFM4OS-69710-1"},{"key":"10.1016\/j.ajo.2026.01.009_bib0024","series-title":"Effects of a Novel TRPV1 antagonist, SJP-0132, On Ocular Surface Dysfunctions in Scopolamine-Induced Dry Eye Rat Model","author":"Atsumi","year":"2024"},{"issue":"14","key":"10.1016\/j.ajo.2026.01.009_bib0025","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.01.009_bib0026","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1167\/iovs.13-13077","article-title":"Impairment of corneal epithelial wound healing in a TRPV1-deficient mouse","volume":"55","author":"Sumioka","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:20:21Z","timestamp":1781857221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"alternative-id":["S0002939426000164"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.009","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1\/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}